Shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) have earned an average recommendation of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $19.25.
Several research firms have recently weighed in on GNMK. BidaskClub downgraded GenMark Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity reiterated a “buy” rating and set a $22.00 price target on shares of GenMark Diagnostics in a research note on Thursday, October 29th. ValuEngine downgraded GenMark Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 10th. Finally, Zacks Investment Research upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 3rd.
Shares of NASDAQ:GNMK opened at $14.60 on Friday. The company has a market capitalization of $1.05 billion, a PE ratio of -35.61 and a beta of 3.02. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.33 and a quick ratio of 3.84. The business has a fifty day moving average price of $13.71 and a two-hundred day moving average price of $14.15. GenMark Diagnostics has a 1 year low of $3.36 and a 1 year high of $20.88.
GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The firm had revenue of $42.65 million during the quarter. GenMark Diagnostics had a negative return on equity of 39.36% and a negative net margin of 16.95%. Sell-side analysts anticipate that GenMark Diagnostics will post -0.25 earnings per share for the current year.
In other GenMark Diagnostics news, VP Alan Baer Maderazo sold 1,994 shares of the firm’s stock in a transaction dated Tuesday, November 24th. The stock was sold at an average price of $13.17, for a total value of $26,260.98. Following the sale, the vice president now owns 248,445 shares of the company’s stock, valued at approximately $3,272,020.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Scott Mendel sold 5,190 shares of the firm’s stock in a transaction dated Tuesday, November 24th. The shares were sold at an average price of $13.17, for a total value of $68,352.30. Following the completion of the sale, the chief executive officer now directly owns 396,830 shares in the company, valued at approximately $5,226,251.10. The disclosure for this sale can be found here. Insiders have sold a total of 163,450 shares of company stock worth $2,285,264 in the last three months. 3.25% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in the business. Harbor Investment Advisory LLC raised its holdings in shares of GenMark Diagnostics by 361.6% in the 3rd quarter. Harbor Investment Advisory LLC now owns 1,731 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 1,356 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of GenMark Diagnostics by 5.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 25,961 shares of the medical equipment provider’s stock valued at $363,000 after acquiring an additional 1,443 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of GenMark Diagnostics in the 3rd quarter valued at about $31,000. Altshuler Shaham Ltd purchased a new position in shares of GenMark Diagnostics during the 3rd quarter valued at about $32,000. Finally, Nisa Investment Advisors LLC raised its holdings in shares of GenMark Diagnostics by 70.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,450 shares of the medical equipment provider’s stock valued at $77,000 after buying an additional 2,250 shares in the last quarter. 90.73% of the stock is currently owned by hedge funds and other institutional investors.
About GenMark Diagnostics
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Featured Story: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.